Drs. Nate Pennell from Cleveland Clinic and Mary Pinder from Moffitt Cancer Center in Tampa, FL sat down with our own Dr. Jack West to discuss early impressions of some of the most provocative research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June.

Here's a growing list of podcasts covering the topics they discussed:

Is it possible to test for biomarkers in lung cancer on a national scale?

Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?

Can we predict which patients will benefit from Tarceva based on a blood test?

Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?

Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?

Can we harness our immune system to fight NSCLC?

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

Is Nintedanib a new agent worthy of becoming a new treatment for advanced NSCLC?

Are molecular markers just for NSCLC?

Could BRAF be a new target in NSCLC?

Can we target KRAS effectively in advanced NSCLC?

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

How do we approach acquired resistance to targeted therapies in lung cancer?

How should we integrate new immunotherapies into treatment strategies for lung cancer?

Is there a place for maintenance therapy in extensive stage SCLC?

This completes the series.  We hope you found this content useful. 

We thank Drs. Nate Pennell and Mary Pinder  for their generosity with their time and expertise in providing this information to the lung cancer community.

We also thank LUNGevity for sponsoring this video series.